This kit is designed for the detection of binding activity between Human EGF and EGFR using a homogeneous LANCE Ultra TR-FRET assay. This assay can facilitate the design and development of therapeutics which competitively inhibit EGF/EGFR interaction.
Item(s) added to cart.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. Streptavidin is labeled with a donor fluorophore (a LANCE Europium chelate) which binds to biotinylated EGF and the EGFR-Fc is recognized by anti-human IgG labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Epidermal Growth Factor Receptor (EGFR, Her1, ErbB1) is a 134 kDa cell surface receptor, part of a four member subfamily of receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4). EGFR binds to a family of proteins called the epidermal growth factors (primarily EGF), which, upon association induces dimerization of the receptor and initiates signal transduction for the promotion of cell survival and growth. Mutations that cause aberrant overexpression of EGF and/or EGFR have been linked with many different cancers such as non-small-cell lung and colon cancers. Drugs are being developed as a means to better treat these types cancer.
|Assay Target Class||Protein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|